Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0
članak: 10 od 21  
Back povratak na rezultate
Acta Facultatis Medicae Naissensis
2009, vol. 26, br. 3, str. 151-157
jezik rada: engleski
vrsta rada: pregledni članak

Blokada renin-angiotenzin-aldosteron sistema - poruka velikih kliničkih studija
Univerzitet u Nišu, Medicinski fakultet, Institut za prevenciju, lečenje i rehabilitaciju reumatičkih i kardioloških bolesti 'Niška Banja' - Niška Banja

e-adresa: vldsanjast@bankerinter.net

Sažetak

Hipertenzija je jedna od najčešćih bolesti u svetu koja pogađa ljudsku populaciju. Mnogobrojni faktori modifikuju krvni pritisak obezbeđujući adekvatnu perfuziju tkiva i oni obuhvataju humoralne medijatore, vaskularnu reaktivnost, cirkulišući krvni volumen, viskoznost krvi, promer krvnih sudova, kardijalni minutni volumen, elastičnost krvnih sudova i neuralnu stimulaciju. Ove promene mogu voditi ka razvoju hipertrofije leve komore, sistolne i dijastolne disfukcije leve komore, koronarne bolesti, srčanih aritmija i srčane insuficijencije. Tokom poslednjih dvadeset godina, brojne studije, kao što su HOPE, EUROPA, VALUE, RESOLVD, LIFE, proučavale su efekte inhibitora konvertujućeg enzima i inhibitora angiotenzin -1 receptora kod hipertenzivnih bolesnika sa hipertrofijom leve komore i koronarnom bolešću. Inhibitori konvertujućeg enzima i inhibitori angiotenzin -1 receptora blokiraju renin-angiotenzin-aldosteron sistem, ali na različitim nivoima kaskade. Nekoliko inhibitora angiotenzin -1 receptora (losartan, valsartan, candesartan) pokazuju sličnu efikasnost u poređenju sa inhibitorima konvertujućeg enzima u redukciji mortaliteta kod bolesnika sa srčanom insuficijencijom, kao i nakon preživelog infarkta miokarda. Ovo je dokazano u nekoliko studija ELITE II, VALHEFT CHARM i ONTARGET. U cilju kompletne blokade renin-angitenzin-aldosteron sistema danas je u upotrebi nova grupa lekova- antagonisti aldosteron receptora.

Ključne reči

arterijska hipertenzija; hipertrofija leve komore; srčana insuficijencija; inhibitori konvertujućeg enzima; blokatori angiotenzinskih 1-receptora

Reference

An, I.S., Rector, T.S., Kuskowski, M., i dr. (2008) Effect of baseline and changes in systolic blood pressure over time on the effectiveness of Valsartan in the Valsartan heart failure trial. Circulation Heart Failure, 1(1): 34
Blankenberg, S., Balion, S., i dr. (2006) Comparative impact of multiple biomarkers and n-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events. Heart Outcomes Prevention Evaluation (HOPE) Study, 114, str. 201-208
Brugts, J.J., Boersma, E., Chonchol, M., Deckers, J., Remme, W., Bertrand, M., i dr. (2007) The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patientswith stable coronary artery disease are not modified by mild to moderate renal insufficiency: Results from the Europa-trial. Circulation, 116: II_783
Jones, D.W., Hall, J.E. (2004) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension, 43(1): 1-3
Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L., Hua, T., Laragh, J., Mcinnes, G.T., Mitchell, L., Plat, F., Schork, A., Smith, B., Zanchetti, A., value Trial Group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363(9426): 2022-31
Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J. (2005) Global burden of hypertension: Analysis of worldwide data. Lancet, 365(9455): 217-23
Klingbeil, A.U., Schneider, M., Martus, P., Messerli, F.H., Schmieder, R.E. (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med, 115(1): 41-6
Masoudi, F.A., Cary, P., i dr. (2005) Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States. Circulation, 112, str. 39-47
Mckelvie, R.S., Rouleau, J., White, M., Afzal, R., Young, J.B., Maggioni, A.P., Held, P., Yusuf, S. (2003) Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J, 24(19): 1727-34
McMurray, J.J.V. (2008) ACE inhibitors in cardiovascular disease-unbeatable?. N Engl J Med, 358:1515-6
Okin, P.M., Devereux, R.B., Harris, K.E., Jern, S., Kjeldsen, S.E., Lindholm, L.H., Dahl, B. (2007) In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: The losartan intervention for endpoint reduction in hypertension. Hypertension, 50(5): 984
Okin, P.M., Devereux, R.B., Harris, K.E., Jern, S., Kjeldsen, S.E., Julius, S. (2007) Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med, 147(5):311-9
Pitt, B., Poole-Wilson, P.A., Segal, R., Martinez, F.A., Dickstein, K., Camm, A.J., Konstam, M.A., Riegger, G., Klinger, G.H., Neaton, J., Sharma, D., Thiyagarajan, B. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The Losartan Heart Failure Survival Study ELITE II. Lancet, 355(9215): 1582-7
Pitt, B., Bakris, G., Ruilope, L.M., i dr. (2008) Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation, 118(16): 1643
Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R.A., Roniker, B., Kleiman, J., Krause, S., Burns, D., Williams, G.H. (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation, 108(15): 1831-8
Schmieder, R.E., i dr. (2007) Renin-angiotensin system and cardiovascular risk. Lancet, 369(9568): 1208
Seferović, P.M., Ristić, A.D., Simeunović, D., Trifunović-Zamaklar, D. (2005) Savremena medikamentozna terapija srčane insuficijencije - između preporuka i prakse. Balneoklimatologija, vol. 29, br. 1, str. 277-288
The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH), The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) (2007) Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 25:1105-87
Weir, M.R. (2007) Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?. Clinical Therapeutics, 29(9): 1803
White, H.D., Aylward, P.E., Huang, Z., i dr. (2005) Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial. Circulation, 112(22): 3391
Yamamoto, K., Masuyama, T., Sakata, Y., Nishikawa, N., Mano, T., Yoshida, J., Miwa, T., Sugawara, M., Yamaguchi, Y., Ookawara, T., Suzuki, K., Hori, M. (2002) Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res, 55(1): 76-82
Young, J.B., Dunlap, M.E., Pfeffer, M.A., Probstfield, J.L., Cohen-Alain,, Dietz, R., Granger, C.B., Hradec, J., Kuch, J., Mckelvie, R.S., Mcmurray, J.J.V., Michelson, E.L., Olofsson, B., Ostergren, J. (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation, 110(17): 2618-26
Yusuf, S., Teo, K.K., Pogue, J., i dr., The ONTARGET investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 358:1547-59
Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342(3): 145-53